320 related articles for article (PubMed ID: 24401210)
1. LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects.
Spillmann F; Van Linthout S; Miteva K; Lorenz M; Stangl V; Schultheiss HP; Tschöpe C
Atherosclerosis; 2014 Jan; 232(1):1-9. PubMed ID: 24401210
[TBL] [Abstract][Full Text] [Related]
2. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.
Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P
Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978
[TBL] [Abstract][Full Text] [Related]
3. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.
Noghero A; Perino A; Seano G; Saglio E; Lo Sasso G; Veglio F; Primo L; Hirsch E; Bussolino F; Morello F
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2280-8. PubMed ID: 22723445
[TBL] [Abstract][Full Text] [Related]
4. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
[TBL] [Abstract][Full Text] [Related]
5. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
Ishibashi M; Filomenko R; Rébé C; Chevriaux A; Varin A; Derangère V; Bessède G; Gambert P; Lagrost L; Masson D
Biochem Pharmacol; 2013 Jul; 86(1):122-9. PubMed ID: 23313547
[TBL] [Abstract][Full Text] [Related]
6. Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Lee TY; Chang PL; Chen WT; Juang HH
Prostate; 2015 May; 75(6):603-15. PubMed ID: 25560459
[TBL] [Abstract][Full Text] [Related]
7. Liver X receptor-α and miR-130a-3p regulate expression of sphingosine 1-phosphate receptor 2 in human umbilical vein endothelial cells.
Fan A; Wang Q; Yuan Y; Cheng J; Chen L; Guo X; Li Q; Chen B; Huang X; Huang Q
Am J Physiol Cell Physiol; 2016 Feb; 310(3):C216-26. PubMed ID: 26669941
[TBL] [Abstract][Full Text] [Related]
8. Palmitic acid-induced apoptosis in pancreatic β-cells is increased by liver X receptor agonist and attenuated by eicosapentaenoate.
Liang H; Zhong Y; Zhou S; Li QQ
In Vivo; 2011; 25(5):711-8. PubMed ID: 21753123
[TBL] [Abstract][Full Text] [Related]
9. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
10. LXR agonist T0901317 upregulates thrombomodulin expression in glomerular endothelial cells by inhibition of nuclear factor‑κB.
Ding H; Li Y; Feng Y; Chen J; Zhong X; Wang N; Wang W; Zhang P; Wang L
Mol Med Rep; 2016 Jun; 13(6):4888-96. PubMed ID: 27082844
[TBL] [Abstract][Full Text] [Related]
11. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
12. Hydrogen sulfide accumulates LDL receptor precursor via downregulating PCSK9 in HepG2 cells.
Huang Y; Ning K; Li WW; Lin G; Hou CL; Wang MJ; Zhu YC
Am J Physiol Cell Physiol; 2020 Dec; 319(6):C1082-C1096. PubMed ID: 32938225
[TBL] [Abstract][Full Text] [Related]
13. Activation of liver X receptor enhances the proliferation and migration of endothelial progenitor cells and promotes vascular repair through PI3K/Akt/eNOS signaling pathway activation.
Yu J; Wang Q; Wang H; Lu W; Li W; Qin Z; Huang L
Vascul Pharmacol; 2014 Sep; 62(3):150-61. PubMed ID: 24892989
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress.
Zhang H; Zhang J; Ungvari Z; Zhang C
Arterioscler Thromb Vasc Biol; 2009 Aug; 29(8):1164-71. PubMed ID: 19478208
[TBL] [Abstract][Full Text] [Related]
15. Liver X receptor agonist treatment reduced splanchnic ischemia and reperfusion injury.
Crisafulli C; Di Paola R; Mazzon E; Paterniti I; Galuppo M; Genovese T; Bramanti P; Cappellani A; Cuzzocrea S
J Leukoc Biol; 2010 Feb; 87(2):309-21. PubMed ID: 20028773
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptor activation inhibits SGLT2-mediated glucose transport in human renal proximal tubular cells.
Chonlaket P; Wongwan T; Soodvilai S
Exp Physiol; 2018 Feb; 103(2):250-260. PubMed ID: 29127736
[TBL] [Abstract][Full Text] [Related]
18. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor.
Blaschke F; Takata Y; Caglayan E; Collins A; Tontonoz P; Hsueh WA; Tangirala RK
Circ Res; 2006 Dec; 99(12):e88-99. PubMed ID: 17110595
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity.
Kim KH; Lee GY; Kim JI; Ham M; Won Lee J; Kim JB
J Lipid Res; 2010 Dec; 51(12):3425-33. PubMed ID: 20847297
[TBL] [Abstract][Full Text] [Related]
20. Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages.
Wang YY; Dahle MK; Steffensen KR; Reinholt FP; Collins JL; Thiemermann C; Aasen AO; Gustafsson JA; Wang JE
Shock; 2009 Nov; 32(5):548-53. PubMed ID: 19295476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
